Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca earnings...

    AstraZeneca earnings hit by waning cholesterol drug sales

    Written by savita thakur thakur Published On 2016-07-29T13:37:17+05:30  |  Updated On 29 July 2016 1:37 PM IST
    AstraZeneca earnings hit by waning cholesterol drug sales

    London : Generic competition to cholesterol buster Crestor in the U.S. market pushed second quarter earnings down by nearly a third at drugmaker AstraZeneca, which is now banking on new cancer medicines to revive its fortunes.


    Core earnings per share, which exclude some items, fell 31 percent to 83 cents as revenue slid 11 percent to $5.60 billion, following the arrival of the first copies of Crestor in the United States in May.


    Industry analysts had on average forecast quarterly revenue of $5.58 billion and earnings of 84 cents a share, according to Thomson Reuters.


    The British company said it continued to expect a low to mid single digit percentage decline in both revenue and core earnings at constant exchange rates for the full year.


    In addition to falling sales of Crestor and other older drugs like Nexium, AstraZeneca also has to deal with a slump in U.S. revenue this year from its nasal spray flu vaccine Flumist, after health officials decided it was not worth using.


    Analysts predict falling group sales and profits this year and next before a return to growth in 2018, when the impact of patent expiries will lessen and sales of newer medicines should start to pick up speed.


    Its new lung cancer drug Tagrisso is already off to a good start, with quarterly sales of $92 million.


    Chief Executive Pascal Soriot, who saw off a takeover attempt by Pfizer in 2014, believes AstraZeneca can become a major player in cancer treatment by developing drugs that bolster the immune system and others that disrupt DNA repair mechanisms used by tumors cells.


    He said he was particularly encouraged by the rapid patient recruitment in the company's immuno-oncology combination drug trials, which are expected to produce make-or-break clinical results in the first half of next year.


    AstraZeneca faces formidable competition in the cancer field from rivals with new medicines that are already on the market, including Roche and Bristol Myers Squibb.


    To free resources for investment in new products, AstraZeneca has been selling off rights to non-core drugs and such "externalisation" deals helped to boost revenue by $134 million in the second quarter. The company said externalisation revenue would increase in the second half of the year.


    Soriot believes he can build a business with annual sales of at least $45 billion by 2023, up from $24.7 billion in 2015, though many analysts question this target, which was first set out during the takeover battle with Pfizer.

    AstraZenecaBristol-Myerscholesterolcholesterol drugCrestorPascal SoriotPfizerRoche
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok